EGFR and neoplasm: Antibody-cytokine fusion proteins, such as anti-CD20/IFN-α, SumIL2/anti-EGFR, an-ti-PD1/IL-21, anti-EGFR/IL-21, arose to target these molecules in the tumor environment and demonstrated an improvement in either increased antitumor efficacy or reduced toxicity [44].